June 13 (Reuters) – Johnson & Johnson: * NEW TALVEY® (TALQUETAMAB-TGVS) PLUS DARZALEX FASPRO® (DARATUMUMAB AND HYALURONIDASE-FIHJ) DATA DEMONSTRATE THE STRENGTH OF A BISPECIFIC COMBINATION IN
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Nasdaq rebounds but remains on track for fourth straight weekly decline
By Colin Barr and Shashwat Chauhan Nov 6 (Reuters) - Technology stocks bounced back on…
Luka Doncic stays hot with 53 points in Lakers' win
VIDEO SHOWS: HIGHLIGHTS OF OS ANGELES LAKERS V PORTLAND TRAIL BLAZERS REGULAR NBA SEASON GAME…
Rugby league-Ponga returns to help New Zealand beat Tonga and reach World Cup final
* Ponga returns three weeks after breaking his arm to help New Zealand reach final…
